Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The EU-PEARL project will take a systematic approach that enables patient-focused, cross company collaborative platform trials.

EU-PEARL logo

For the first time, 36 world-leading institutions among European university hospitals, research centers, patient groups, non-profit product developers and pharmaceutical companies are coming together for the first time, to shape the adaptive clinical trial platform of the future.

The project, called EU Patient-cEntric clinicAl tRial pLatforms (EU-PEARL), is a unique public-private strategic partnership funded by the Innovative Medicines Initiative (IMI) to conceptualise and lead the design of an integrated research platform, enabling patient-centric drug development in Europe.

As one of the 36 partners, researchers at NDORMS will contribute to the creation of patient data networks, and to the use of common data models for clinical trial data.

Participants in EU-PEARL have the ambition of transforming the current approach of conducting single-compound clinical trials into the use of cross-company Integrated Research Platforms (IRPs), specifically for early development and focused on patients' interests, while seeking opportunities to address medical needs through the advancement of novel molecules.

The intent is to shape future clinical trials that will be more patient friendly by design and patient focused by outcome in four diseases areas: Major Depressive Disorder, Tuberculosis, Non-Alcoholic Steatohepatitis and Neurofibromatosis; and provide the framework for designing and executing IRPs in other disease areas.

The current model of evaluating one drug at a time in one trial often results in a long, sequential cycle of drug development, substantial investment and delays in getting the most effective treatments to patients. Competing trials challenge patient recruitment and patients often struggle to navigate the complex trial landscape to find the optimum clinical study.

A platform trial is a clinical trial with a single master protocol in which multiple treatments are evaluated simultaneously. Adaptive platform designs offer flexible features such as removing a treatment group for futility or adding new groups and treatments to be tested during the course of the trial. 

Dani Prieto-Alhambra, Professor of Pharmaco- and Device Epidemiology at NDORMS, University of Oxford said: “EU PEARL will be a game changer that will facilitate the conducting of platform trials in Europe, and the speedy and reproducible analysis of the resulting data”.

The five pillars of EU-PEARL

EU-PEARL is based on these pillars:

The hospital hubs: The clinical network of hospitals will provide experienced environment for clinical trials and an ideal space to foster interaction of all stakeholders.

The patients: EU-PEARL will foster an environment for patient engagement to play an important role in approaches to change the way clinical trials are conducted.

Methods and Tools: EU-PEARL will develop an integrated set of methods and tools for the planning, implementation and analysis of adaptive platform trials.

Regulatory framework: To provide the necessary standards to ensure that the collection and inclusion, processing and use of health and wellbeing data complies with European and national data protection and ethical regulations, regulatory requirements and legislation.

Data governance: This project will also create the associated data governance ecosystem focusing on interoperability and quality of investigator/patient data; robust policies for access to global data and the creation of a governance structure for transparency, engagement and utilisation.

Supported by

This project has received funding from the Innovative Medicines Initiative 2 Join Undertaking under grant agreement No 853966. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The total budget is 26M€ for a project duration of 42 months.

Similar stories

New guidelines to improve reporting standards of studies that investigate causal mechanisms

Researchers at NDORMS have developed a new set of guidelines for reporting mediation analyses in health research.

New Associate Professors announced at NDORMS

The Medical Sciences Division has awarded the title of Associate Professor to five senior researchers at NDORMS.

COVID-19 vaccines shown to reduce infection by 90% in nursing homes

A new collaborative study between the Catalan Institute of Health, the Public Health Secreatariat of Catalonia, and the Centre for Statistics in Medicine, NDORMS, at the University of Oxford have confirmed that COVID-19 vaccines greatly reduce infections, hospitalisations and mortality for up to 6 months.

The Kennedy Institute completes its roof extension

Building work at the Kennedy Institute of Rheumatology has finished, providing a new third floor that houses additional meeting and collaboration space for data science and offices for the management of clinical trials.

Unlocking the secrets of the microbiome

Jethro Johnson, Deputy Director of the Oxford Centre for Microbiome Research explains how the centre is building a research community to understand the microbiome and harness its power to promote health and prevent disease.

Into the future: watching biology unfold

As part of the University of Oxford’s mission to provide its researchers with the newest state-of-the-art optical imaging equipment and as part of a strategic partnership with the Kennedy Institute of Rheumatology (KIR), the Institute of Developmental and Regenerative Medicine (IDRM), and Carl Zeiss AG (ZEISS), ZEISS has installed a ZEISS Lattice Lightsheet 7 microscope at the KIR.